It was estimated that as of 2023, around **** million people in the United States had been diagnosed with diabetes. The number of people diagnosed with diabetes in the U.S. has increased in recent years and the disease is now a major health issue. Diabetes is now the seventh leading cause of death in the United States, accounting for ******percent of all deaths. What is prediabetes? A person is considered to have prediabetes if their blood sugar levels are higher than normal but not high enough to be diagnosed with type 2 diabetes. As of 2021, it was estimated that around ** million men and ** million women in the United States had prediabetes. However, according to the CDC, around ** percent of these people do not know they have this condition. Not only does prediabetes increase the risk of developing type 2 diabetes, but also increases the risk of heart disease and stroke. The states with the highest share of adults who had ever been told they have prediabetes are California, Hawaii, and New Mexico. The prevalence of diabetes in the United States As of 2023, around *** percent of adults in the United States had been diagnosed with diabetes, an increase from ****percent in the year 2000. Diabetes is much more common among older adults, with around ** percent of those aged 60 years and older diagnosed with diabetes, compared to just ****percent of those aged 20 to 39 years. The states with the highest prevalence of diabetes among adults are West Virginia, Mississippi, and Louisiana, while Utah and Colorado report the lowest rates. In West Virginia, around ** percent of adults have been diagnosed with diabetes.

As of 2021, there were an estimated five million women in the United States with diabetes who had not yet been diagnosed. All together, there were some 29.4 million adults in the United States who had been diagnosed with diabetes as of that time. This statistic shows the estimated number of adults with diabetes in the United States as of 2021, by gender.

United States US: Diabetes Prevalence: % of Population Aged 20-79 data was reported at 10.790 % in 2017. United States US: Diabetes Prevalence: % of Population Aged 20-79 data is updated yearly, averaging 10.790 % from Dec 2017 (Median) to 2017, with 1 observations. United States US: Diabetes Prevalence: % of Population Aged 20-79 data remains active status in CEIC and is reported by World Bank. The data is categorized under Global Database’s USA – Table US.World Bank: Health Statistics. Diabetes prevalence refers to the percentage of people ages 20-79 who have type 1 or type 2 diabetes.; ; International Diabetes Federation, Diabetes Atlas.; Weighted average;

In 2023, the prevalence of diagnosed diabetes in the United States among people aged 18 and over amounted to *** percent. This was an increase from *** percent in the year 2000. How many people in the United States have diabetes? It was estimated that in 2023, almost **** million people in the United States had been diagnosed with diabetes. The number of people living with diabetes has increased over the past few decades, with only **** million people living with diabetes in the year 1980. Diabetes in the United States is more common among older adults, with around ** percent of those aged 60 years and older diagnosed with diabetes, compared to ** percent of those aged 40 to 59 years. Leading diabetic states In 2023, the U.S. states with the highest prevalence of diagnosed diabetes were West Virginia, Mississippi, and Louisiana. Just over ** percent of adults in West Virginia had diabetes that year. In Utah, just under ***** percent of adults have been diagnosed with diabetes, the lowest share in the United States.

It was estimated that as of 2022 around 24.4 million people in the United States had been diagnosed with diabetes. The number of people diagnosed with diabetes in the U.S. has increased in recent years and the disease is now a major health issue. Diabetes is now the eighth leading cause of death in the United States, accounting for three percent of all deaths.

What is prediabetes? A person is considered to have prediabetes if their blood sugar levels are higher than normal but not high enough to be diagnosed with type 2 diabetes. As of 2021, it was estimated that around 53 million men and 44 million women in the United States had prediabetes. However, according to the CDC, around 80 percent of these people do not know they have this condition. Not only does prediabetes increase the risk of developing type 2 diabetes, but also increases the risk of heart disease and stroke. The states with the highest share of adults who had ever been told they have prediabetes are Hawaii, California, and Alaska.

The prevalence of diabetes in the United States As of 2022, around 8.4 percent of adults in the United States had been diagnosed with diabetes, an increase from six percent in the year 2000. Diabetes is much more common among older adults, with almost a quarter of those aged 65 years and older diagnosed with diabetes, compared to just three percent of those aged 18 to 44 years. The states with the highest prevalence of diabetes among adults are Alabama, Mississippi, and West Virginia, while Colorado and Alaska report the lowest rates. In Alabama, around 17 percent of adults have been diagnosed with diabetes.

Population-based county-level estimates for diagnosed (DDP), undiagnosed (UDP), and total diabetes prevalence (TDP) were acquired from the Institute for Health Metrics and Evaluation (IHME) for the years 2004-2012 (Evaluation 2017). Prevalence estimates were calculated using a two-stage approach. The first stage used National Health and Nutrition Examination Survey (NHANES) data to predict high fasting plasma glucose (FPG) levels (≥126 mg/dL) and/or hemoglobin A1C (HbA1C) levels (≥6.5% [48 mmol/mol]) based on self-reported demographic and behavioral characteristics (Dwyer-Lindgren, Mackenbach et al. 2016). This model was then applied to Behavioral Risk Factor Surveillance System (BRFSS) data to impute high FPG and/or A1C status for each BRFSS respondent (Dwyer-Lindgren, Mackenbach et al. 2016). The second stage used the imputed BRFSS data to fit a series of small area models, which were used to predict the county-level prevalence of each of the diabetes-related outcomes (Dwyer-Lindgren, Mackenbach et al. 2016). Diagnosed diabetes was defined as the proportion of adults (age 20+ years) who reported a previous diabetes diagnosis, represented as an age-standardized prevalence percentage. Undiagnosed diabetes was defined as proportion of adults (age 20+ years) who have a high FPG or HbA1C but did not report a previous diagnosis of diabetes. Total diabetes was defined as the proportion of adults (age 20+ years) who reported a previous diabetes diagnosis and/or had a high FPG/HbA1C. The age-standardized diabetes prevalence (%) was used as the outcome. The EQI was constructed for 2000-2005 for all US counties and is composed of five domains (air, water, built, land, and sociodemographic), each composed of variables to represent the environmental quality of that domain. Domain-specific EQIs were developed using principal components analysis (PCA) to reduce these variables within each domain while the overall EQI was constructed from a second PCA from these individual domains (L. C. Messer et al., 2014). To account for differences in environment across rural and urban counties, the overall and domain-specific EQIs were stratified by rural urban continuum codes (RUCCs) (U.S. Department of Agriculture, 2015). This dataset is not publicly accessible because: EPA cannot release personally identifiable information regarding living individuals, according to the Privacy Act and the Freedom of Information Act (FOIA). This dataset contains information about human research subjects. Because there is potential to identify individual participants and disclose personal information, either alone or in combination with other datasets, individual level data are not appropriate to post for public access. Restricted access may be granted to authorized persons by contacting the party listed. It can be accessed through the following means: Human health data are not available publicly. EQI data are available at: https://edg.epa.gov/data/Public/ORD/NHEERL/EQI. Format: Data are stored as csv files. This dataset is associated with the following publication: Jagai, J., A. Krajewski, S. Shaikh, D. Lobdell, and R. Sargis. Association between environmental quality and diabetes in the U.S.A.. Journal of Diabetes Investigation. John Wiley & Sons, Inc., Hoboken, NJ, USA, 11(2): 315-324, (2020).

As of 2021, there were an estimated 4.3 million non-Hispanic white adults in the United States with diabetes who had not yet been diagnosed. All together, there were some 29.4 million adults in the United States who had been diagnosed with diabetes as of that time. This statistic shows the estimated number of adults with diabetes in the United States as of 2021, by race/ethnicity.

This dataset contains information on the proportion by age, total number, male and female and sex of adults of adults diagnosed with diabetes, collected from the system of health-related telephone surveys, the Behavioral Risk Factor Surveillance System (BRFSS), conducted in more than 400,000 patients, from 50 states in the US, the District of Columbia and three US territories.

Population-based county-level estimates for prevalence of DC were obtained from the Institute for Health Metrics and Evaluation (IHME) for the years 2004-2012 (16). DC prevalence rate was defined as the propor-tion of people within a county who had previously been diagnosed with diabetes (high fasting plasma glu-cose 126 mg/dL, hemoglobin A1c (HbA1c) of 6.5%, or diabetes diagnosis) but do not currently have high fasting plasma glucose or HbA1c for the period 2004-2012. DC prevalence estimates were calculated using a two-stage approach. The first stage used National Health and Nutrition Examination Survey (NHANES) data to predict high fasting plasma glucose (FPG) levels (≥126 mg/dL) and/or HbA1C levels (≥6.5% [48 mmol/mol]) based on self-reported demographic and behavioral characteristics (16). This model was then applied to Behavioral Risk Factor Surveillance System (BRFSS) data to impute high FPG and/or HbA1C status for each BRFSS respondent (16). The second stage used the imputed BRFSS data to fit a series of small area models, which were used to predict county-level prevalence of diabetes-related outcomes, including DC (16). The EQI was constructed for 2006-2010 for all US counties and is composed of five domains (air, water, built, land, and sociodemographic), each composed of variables to represent the environmental quality of that _domain. Domain-specific EQIs were developed using principal components analysis (PCA) to reduce these variables within each _domain while the overall EQI was constructed from a second PCA from these individual domains (L. C. Messer et al., 2014). To account for differences in environment across rural and urban counties, the overall and _domain-specific EQIs were stratified by rural urban continuum codes (RUCCs) (U.S. Department of Agriculture, 2015). Results are reported as prevalence rate differences (PRD) with 95% confidence intervals (CIs) comparing the highest quintile/worst environmental quality to the lowest quintile/best environmental quality expo-sure metrics. PRDs are representative of the entire period of interest, 2004-2012. Due to availability of DC data and covariate data, not all counties were captured, however, the majority, 3134 of 3142 were utilized in the analysis. This dataset is not publicly accessible because: EPA cannot release personally identifiable information regarding living individuals, according to the Privacy Act and the Freedom of Information Act (FOIA). This dataset contains information about human research subjects. Because there is potential to identify individual participants and disclose personal information, either alone or in combination with other datasets, individual level data are not appropriate to post for public access. Restricted access may be granted to authorized persons by contacting the party listed. It can be accessed through the following means: Human health data are not available publicly. EQI data are available at: https://edg.epa.gov/data/Public/ORD/NHEERL/EQI. Format: Data are stored as csv files. This dataset is associated with the following publication: Jagai, J., A. Krajewski, K. Price, D. Lobdell, and R. Sargis. Diabetes control is associated with environmental quality in the USA. Endocrine Connections. BioScientifica Ltd., Bristol, UK, 10(9): 1018-1026, (2021).

Diabetes Treatment Market Outlook

The global diabetes treatment market size was valued at approximately $50 billion in 2023 and is projected to reach around $90 billion by 2032, growing at a compound annual growth rate (CAGR) of 6.5%. This significant growth is primarily driven by the increasing prevalence of diabetes worldwide, advancements in medical technology, and a rising awareness of diabetes management and treatment options.

One of the primary growth factors for the diabetes treatment market is the increasing prevalence of diabetes globally. According to the International Diabetes Federation, the number of people with diabetes is expected to rise from 463 million in 2019 to 700 million by 2045. This alarming increase highlights the urgent need for effective diabetes management and treatment solutions, driving demand in the market. Additionally, lifestyle changes such as urbanization and diet shifts contribute to the rising diabetes rates, further fueling market growth.

Technological advancements in diabetes treatment are another significant growth catalyst. Innovations in insulin delivery systems, continuous glucose monitoring (CGM) devices, and artificial pancreas systems are transforming diabetes care. Improved accuracy, convenience, and patient compliance offered by these technologies enhance diabetes management, thereby boosting market demand. The integration of digital health technologies, such as mobile health apps and telemedicine, also plays a crucial role in supporting diabetes management and monitoring, propelling market growth.

Government initiatives and supportive policies are also driving the growth of the diabetes treatment market. Many governments across the globe are implementing national diabetes programs to improve diabetes care and management. These programs often include funding for research, subsidies for diabetes medications and devices, and public awareness campaigns. Furthermore, collaborations between public and private sectors are fostering innovation and accessibility in diabetes treatment, which is expected to sustain market growth over the forecast period.

From a regional perspective, North America holds a significant share of the diabetes treatment market due to the high prevalence of diabetes, well-established healthcare infrastructure, and strong presence of key market players. Europe follows closely, driven by a growing diabetic population and favorable reimbursement policies. The Asia Pacific region is anticipated to witness the fastest growth, attributed to increasing urbanization, rising healthcare expenditure, and a large undiagnosed diabetic population. Meanwhile, Latin America and the Middle East & Africa regions are expected to experience steady growth owing to improving healthcare access and growing awareness of diabetes management.

Product Type Analysis

In the diabetes treatment market, the product type segment is categorized into Insulin, Oral Hypoglycemic Agents, Non-Insulin Injectable Drugs, and Others. Insulin remains a cornerstone in diabetes management, particularly for individuals with Type 1 diabetes and advanced Type 2 diabetes. The development of various insulin formulations, such as rapid-acting, long-acting, and premixed insulins, caters to the diverse needs of diabetic patients. Additionally, innovations like insulin pens and pumps enhance the convenience and accuracy of insulin administration, supporting the growth of this segment.

Oral Hypoglycemic Agents (OHAs) represent another critical segment in diabetes treatment, particularly for Type 2 diabetes management. OHAs include medications such as metformin, sulfonylureas, DPP-4 inhibitors, and SGLT-2 inhibitors, which help to lower blood glucose levels through different mechanisms. The increasing prevalence of Type 2 diabetes, along with a growing focus on combination therapies to improve glycemic control, is driving the demand for OHAs. Additionally, the development of new classes of oral medications with improved efficacy and safety profiles is expected to further boost this segment.

Non-Insulin Injectable Drugs, including GLP-1 receptor agonists and amylin analogs, offer alternative treatment options for diabetes management. These injectable drugs help to control blood sugar levels and provide additional benefits such as weight loss and cardiovascular protection. The growing preference for non-insulin injectables among patients and healthcare providers is contributing to the expansion of this segment. Moreover, ongoing research and development efforts aimed at enhancing the delivery and efficacy of these

Data for cities, communities, and City of Los Angeles Council Districts were generated using a small area estimation method which combined the survey data with population benchmark data (2022 population estimates for Los Angeles County) and neighborhood characteristics data (e.g., U.S. Census Bureau, 2017-2021 American Community Survey 5-Year Estimates). This indicator is based on self-report of ever being diagnosed with diabetes (type 1 or 2).Diabetes is associated with decreased life expectancy, heart disease and stroke, lower limb amputations, kidney disease, and blindness. It is also closely linked with obesity. Cities and communities can help prevent diabetes by adopting policies that support healthy food retail and physical activity and improve access to preventive care services.For more information about the Community Health Profiles Data Initiative, please see the initiative homepage.

This web map is part of the Centers for Disease Control and Prevention (CDC) PLACES. It provides model-based estimates of diagnosed diabetes prevalence among adults aged 18 years and older at county, place, census tract, and ZCTA levels in the United States. PLACES is an expansion of the original 500 Cities Project and a collaboration between the CDC, the Robert Wood Johnson Foundation, and the CDC Foundation. Data sources used to generate these estimates include the Behavioral Risk Factor Surveillance System (BRFSS), Census 2020 population counts or Census annual county-level population estimates, and the American Community Survey (ACS) estimates. For detailed methodology see www.cdc.gov/places. For questions or feedback send an email to places@cdc.gov.Measure name used for diagnosed diabetes is DIABETES.

Around ** percent of the global adult population suffered from diabetes in 2024 - by the year 2050 this number is expected to rise to ** percent. Diabetes, or diabetes mellitus, refers to a group of metabolic disorders that result in chronic high blood sugar levels. Diabetes can lead to serious health complications, such as cardiovascular disease, chronic kidney disease, and stroke, and is now among the top ten leading causes of death worldwide. Prevalence Diabetes is a global problem affecting many countries. China currently has the largest number of diabetics worldwide, with some *** million people suffering from the disease. However, the highest prevalence of diabetes is found in Pakistan, followed by the Marshall Islands and Kuwait. Rates of diabetes have increased in many countries in recent years, as have rates of obesity, one of the leading risk factors for the disease. Outlook It is predicted that diabetes will continue to be a problem in the future. Africa is expected to see a *** percent increase in the number of diabetics in the region from 2024 to 2050, while North America and the Caribbean are expected to see an increase of ** percent. In 2050, China is predicted to be the country with the highest number of diabetics worldwide, with the United States accounting for the fourth-highest number.

The US diabetes devices market, a significant segment of the global market, is experiencing robust growth, driven by the rising prevalence of diabetes and an aging population. The market, valued at approximately $25.16 billion in 2025, is projected to expand at a Compound Annual Growth Rate (CAGR) of 6.27% from 2025 to 2033. This growth is fueled by several key factors: increasing adoption of continuous glucose monitoring (CGM) systems offering improved diabetes management, technological advancements leading to smaller, more user-friendly devices, and growing awareness of the benefits of proactive diabetes care. The market is segmented into monitoring and management devices. Within monitoring, self-monitoring blood glucose (SMBG) devices, including glucometers, test strips, and lancets, remain a substantial portion, although CGM is experiencing faster growth due to its real-time data capabilities and improved patient outcomes. The management device segment is dominated by insulin delivery systems like insulin pumps, syringes, pens, and jet injectors, with insulin pumps showing particularly strong growth prospects due to their convenience and efficacy in managing insulin delivery. Competitive intensity is high, with major players like Abbott, Medtronic, Dexcom, and Novo Nordisk vying for market share through continuous innovation and strategic partnerships. The North American region, particularly the US, holds a significant market share owing to high diabetes prevalence, advanced healthcare infrastructure, and strong regulatory support for innovative medical technologies. The market's growth trajectory is expected to remain positive through 2033, although certain restraints could influence the pace. These include high costs associated with some devices, particularly CGMs and insulin pumps, creating access barriers for some patients. However, increasing insurance coverage and the development of more affordable alternatives are mitigating these challenges. Furthermore, technological advancements, such as the integration of artificial intelligence and machine learning in diabetes management, are expected to further enhance the market's potential. Companies are focusing on developing integrated systems that combine CGM with insulin delivery, providing a more holistic approach to diabetes management. This trend will likely drive further growth and consolidation within the market. Future success will depend on companies' ability to innovate, offer competitive pricing strategies, and address the evolving needs of patients. Recent developments include: August 2023: The US Food and Drug Administration (FDA) has granted clearance for Roche's Accu-Chek Solo micropump system, a tubing-free "patch" pump for people with diabetes who use insulin., March 2022: Dexcom released G7 first in the U.K. and was expected to expand the launch across Europe throughout 2022. Meanwhile, the CGM system currently is under review by the Food and Drug Administration for an eventual U.S. release.. Key drivers for this market are: Increasing Number of Preterm and Low-weight Births, Advanced Technology in Fetal and Prenatal Monitoring. Potential restraints include: Stringent Regulatory Procedures. Notable trends are: Growing Diabetes and Obesity Population in the United States.

1. Data were provided by the Centers for Disease Control and Prevention (CDC), Division of Population Health, Epidemiology and Surveillance Branch. The project was funded by the Robert Wood Johnson Foundation (RWJF) in conjunction with the CDC Foundation. This is a filtered subset of the 500 Cities data that provides model-based small area estimates for 27 measures of chronic disease related to unhealthy behaviors (5), health outcomes (13), and use of preventive services (9). It represents a first-of-its kind effort to release information on a large scale for cities and for small areas within those cities. It includes estimates for the 500 largest US cities and approximately 28,000 census tracts within these cities. These estimates can be used to identify emerging health problems and to inform development and implementation of effective, targeted public health prevention activities. Because the small area model cannot detect effects due to local interventions, users are cautioned against using these estimates for program or policy evaluations. Data sources used to generate these measures include Behavioral Risk Factor Surveillance System (BRFSS) data 2015, Census Bureau 2010 census population data, and American Community Survey (ACS) 2011-2015 estimates. More information about the methodology can be found at www.cdc.gov/500cities.

IntroductionThe American Diabetes Association (ADA) recommends screening for prediabetes and diabetes (dysglycemia) starting at age 35, or younger than 35 years among adults with overweight or obesity and other risk factors. Diabetes risk differs by sex, race, and ethnicity, but performance of the recommendation in these sociodemographic subgroups is unknown.MethodsNationally representative data from the National Health and Nutrition Examination Surveys (2015-March 2020) were analyzed from 5,287 nonpregnant US adults without diagnosed diabetes. Screening eligibility was based on age, measured body mass index, and the presence of diabetes risk factors. Dysglycemia was defined by fasting plasma glucose ≥100mg/dL (≥5.6 mmol/L) or haemoglobin A1c ≥5.7% (≥39mmol/mol). The sensitivity, specificity, and predictive values of the ADA screening criteria were examined by sex, race, and ethnicity.ResultsAn estimated 83.1% (95% CI=81.2-84.7) of US adults were eligible for screening according to the 2023 ADA recommendation. Overall, ADA’s screening criteria exhibited high sensitivity [95.0% (95% CI=92.7-96.6)] and low specificity [27.1% (95% CI=24.5-29.9)], which did not differ by race or ethnicity. Sensitivity was higher among women [97.8% (95% CI=96.6-98.6)] than men [92.4% (95% CI=88.3-95.1)]. Racial and ethnic differences in sensitivity and specificity among men were statistically significant (P=0.04 and P=0.02, respectively). Among women, guideline performance did not differ by race and ethnicity.DiscussionThe ADA screening criteria exhibited high sensitivity for all groups and was marginally higher in women than men. Racial and ethnic differences in guideline performance among men were small and unlikely to have a significant impact on health equity. Future research could examine adoption of this recommendation in practice and examine its effects on treatment and clinical outcomes by sex, race, and ethnicity.

Diabetes Management Market Outlook

The global diabetes management market size was valued at USD 58.4 billion in 2023 and is projected to reach USD 94.6 billion by 2032, growing at a CAGR of 5.3% during the forecast period. The increasing prevalence of diabetes worldwide, coupled with rising awareness about diabetes management and technological advancements in diabetes care devices, are significant growth factors driving this market. The aging population and lifestyle-related factors contributing to the rising incidence of diabetes further bolster market growth.

One of the primary growth factors for the diabetes management market is the escalating incidence and prevalence of diabetes globally. According to the International Diabetes Federation (IDF), approximately 537 million adults (20-79 years) were living with diabetes in 2021, a number projected to rise to 643 million by 2030. This alarming increase necessitates effective diabetes management solutions, propelling market growth. Additionally, the growing awareness about the long-term complications of diabetes and the importance of proper management is fueling the adoption of advanced diabetes care products and technologies.

Technological advancements in diabetes care devices are another critical factor contributing to market growth. Innovations such as continuous glucose monitoring (CGM) systems, artificial pancreas systems, and smart insulin pens have revolutionized diabetes management, improving patient outcomes and quality of life. The integration of digital health technologies, such as mobile applications and cloud-based platforms, with diabetes care devices allows for real-time monitoring and data sharing, enhancing diabetes management and patient compliance. These advancements are expected to continue driving the market during the forecast period.

The increasing adoption of diabetes management solutions in emerging markets presents significant growth opportunities. Countries in the Asia Pacific, Latin America, and Middle East & Africa regions are witnessing a surge in diabetes prevalence due to urbanization, changing lifestyles, and dietary habits. Government initiatives to improve healthcare infrastructure, increase awareness, and subsidize diabetes care products further support market growth in these regions. Additionally, the rising disposable incomes and growing middle-class population in these regions are driving the demand for advanced diabetes management solutions.

Regionally, North America dominated the diabetes management market in 2023, owing to the high prevalence of diabetes, well-established healthcare infrastructure, and favorable reimbursement policies. However, the Asia Pacific region is expected to witness the highest growth rate during the forecast period, driven by the increasing diabetic population, improving healthcare facilities, and rising awareness about diabetes management. Europe also holds a significant market share, supported by the high prevalence of diabetes and robust healthcare systems in countries like Germany, the UK, and France.

Product Type Analysis

The diabetes management market is segmented by product type into insulin, insulin delivery devices, blood glucose monitoring devices, continuous glucose monitoring devices, and others. Insulin remains a cornerstone in the treatment of diabetes, especially for Type 1 diabetes and advanced Type 2 diabetes. With the increasing prevalence of diabetes, the demand for insulin is expected to rise. Technological advancements in insulin formulations, such as long-acting and rapid-acting insulins, have improved patient compliance and outcomes, further driving the market growth.

Insulin delivery devices, including insulin pens, pumps, and jet injectors, have seen significant advancements in recent years. These devices offer ease of use, precision in insulin delivery, and improved patient compliance. Insulin pumps, in particular, have gained popularity due to their ability to provide continuous insulin infusion, mimicking the body's natural insulin release. The growing adoption of insulin delivery devices is driven by the rising diabetic population, technological advancements, and increased awareness about the benefits of these devices.

Blood glucose monitoring devices are essential for effective diabetes management, allowing patients to monitor their blood glucose levels regularly. The market for these devices includes blood glucose meters, test strips, lancets, and lancing devices. The increasing prevalence of diabetes and the growing awareness about the importance of regular blood glu

This dataset provides diabetes prevalence estimates by county and sex for the prevalence of diagnosed, undiagnosed, and total diabetes, as well as rates of diagnosis and effective treatment for 1999-2012. The dataset contains estimates for all states and counties, the District of Columbia, and the United States as a whole.

Snapshot img

Diabetes Management Devices Market Size 2024-2028

The diabetes management devices market size is forecast to increase by USD 13.98 bn at a CAGR of 7.68% between 2023 and 2028.

The market is witnessing significant growth due to the rising global burden of diabetes and the increasing focus on advanced technologies such as artificial pancreas systems. These systems utilize insulin pumps and continuous glucose monitoring sensors to automatically adjust insulin delivery based on real-time glucose levels. Additionally, the integration of artificial intelligence and data analytics in diabetes management devices is revolutionizing the industry, enabling remote patient monitoring and personalized treatment plans. Other trends include the development of insulin pens with advanced features and the adoption of spectroscopy technology for non-invasive blood glucose monitoring. However, the prohibitive cost of diabetes care devices remains a major challenge for market growth.Overall, the market is expected to experience robust growth In the coming years, driven by technological advancements and the increasing prevalence of diabetes.

What will be the Size of the Diabetes Management Devices Market during the Forecast Period?

Request Free SampleThe market encompasses a range of technologies designed to assist individuals in managing their diabetes, including insulin delivery devices, mobile health applications, and disease management tools. With the global diabetic population projected to reach over 592 million by 2035, driven by factors such as obesity rates, smoking, and high cholesterol levels, the market for diabetes care devices is experiencing significant growth. Hospitals and specialty clinics are increasingly adopting minimally invasive devices, such as diabetes lancet devices and diabetes tracker devices, to improve patient care and outcomes. Type 1 diabetes, an autoimmune disease characterized by insulin deficiency, and Type 2 diabetes, often associated with insulin resistance, both require ongoing management to prevent complications, including kidney failure, gangrene, and lower limb amputation.Insulin delivery devices, including insulin pens and blood glucose level monitoring systems, are essential tools in managing both types of diabetes. The market for diabetes management devices is expected to continue expanding as technology advances and the global population ages.

How is this Diabetes Management Devices Industry segmented and which is the largest segment?

The diabetes management devices industry research report provides comprehensive data (region-wise segment analysis), with forecasts and estimates in 'USD billion' for the period 2024-2028, as well as historical data from 2018-2022 for the following segments. ProductBlood glucose monitoring devicesInsulin delivery systemsDistribution ChannelOfflineOnlineGeographyNorth AmericaUSEuropeGermanyUKFranceAsiaChinaRest of World (ROW)

By Product Insights

The blood glucose monitoring devices segment is estimated to witness significant growth during the forecast period. Diabetes management devices play a crucial role in monitoring and managing blood glucose levels for individuals with diabetes. These devices include a range of products such as insulin delivery systems, continuous monitoring systems, and glucose monitoring devices. Insulin delivery devices, including insulin pumps and pens, facilitate precise insulin administration. Continuous monitoring systems, such as continuous glucose monitoring systems (CGMs) and Mobi insulin pumps, provide real-time glucose level data through wireless transmission and dedicated apps. Glucowear, a continuous glucose monitoring system, offers non-invasive transdermal sensors and spectroscopy technology. Hospital pharmacies, retail pharmacies, and online pharmacies stock these diabetes care devices. The increasing prevalence of diabetes among the obese, elderly population, and those with conditions like high cholesterol levels, smoking, and inactive lifestyles necessitates effective diabetes management.Disease management is essential to prevent complications like kidney failure, gangrene, lower limb amputation, heart attack, blindness, and stroke. Diabetes tracker devices, such as diabetes monitoring software and artificial pancreas systems, help healthcare providers analyze glucose patterns and create treatment plans. User-friendly interfaces, visual representations, and medication adherence features enhance the efficacy of treatment. In summary, diabetes management devices, including insulin delivery devices, continuous monitoring systems, and glucose monitoring devices, are essential tools for managing diabetes and preventing complications. These devices offer precision, flexibility, and smart features, making diabetes care more accessible and convenient for individuals with diabetes. Hospital segment, diagnostic centers, diabetes clinics, and health

US population simulation estimates of diabetes prevalence (95% CI) during pregnancy in non-Hispanic white and non-Hispanic black women ages 15–44.